

Which type of drugs are included in Cortellis?

Cortellis Competitive Intelligence


Cortellis Competitive Intelligence gathers data from hundreds of scientific and commercial sources to provide the information you need when evaluating drugs in your field of research. All therapy areas are included as well as rare diseases.

Cortellis focuses on prescription drugs -patent protected- and developed for human use since 1990s. Coverage starts in discovery phase and continues through preclinical, clinical trials, approval process until the drug is launched or discontinued.

Small molecules, biologics, drug combinations, biosimilars, salts and new versions of existing drugs with an element of innovation -like a new formulation- are also included in Cortellis.

The following are examples of types of drugs you will find and how to search for them.

1. Type the name of the drug in Quick Search.



2. Original and related drugs will be listed in the results table where indexing information is available to help you quickly identify mechanism of action, indication, company, and other details for each drug.

| Drug Name | Active Companies | Active Indications | Target-based Actions | Highest Status | Regulatory Designations |
|---|---|--|---|--|--|
| sofosbuvir | Biotoscana International; Gilead Sciences Inc | Hepatitis C virus infection | Hepatitis C virus NSSB polymerase inhibitor | Launched (Hepatitis C virus infection - US - Dec-2013) | Breakthrough Therapy; Fast Track; Orphan Drug; Paediatric Investigation Plan |
| sofosbuvir + ledipasvir (fixed-combination/oral, HCV/HBV), Gilead | Biotoscana International; Gilead Sciences Inc | Hepatitis B virus infection; Hepatitis C virus infection | Hepatitis C virus NSSB polymerase inhibitor; Hepatitis C virus protein NS5A inhibitor | | |

Drug combinations are included in Cortellis as separate records.

Results Per page: 25 Sort by: Relevance Order Columns View

| Drug Name | Active Companies | Active Indications | Target-based Actions | Highest Status | Regulatory Designations |
|--|---|---|--|------------------|-------------------------|
| lacosamide | Filters : [0] Daiichi Sankyo Co Ltd; NewBridge Pharmaceuticals Ltd; Orient Europharma; UCB Pharma GmbH; UCB SA | Filters : [0] Epilepsy; Partial seizure; Tonic clonic epilepsy | Filters : [0] Dihydropyrimidinase related protein 2 modulator; Sodium channel modulator | | |
| lacosamide (oral extended release, epilepsy), Adamas | Adamas Pharmaceuticals Inc | Epilepsy | Dihydropyrimidinase related protein 2 modulator; Sodium channel modulator | Phase 1 Clinical | |

New formulations can also be found by searching the original drug name.

Results Per page: 25 Sort by: Last Change Date Most Recent Order Columns View

| Drug Name | Active Companies | Active Indications | Target-based Actions | Highest Status | Regulatory Designations |
|--|--|--|--|--|-------------------------|
| bevacizumab | Filters : [0] Chugai Pharmaceutical Co Ltd; F Hoffmann-La Roche AG; Genentech Inc; Roche Holding AG | Filters : [0] Cerebral edema; Colorectal tumor; Endometrioid carcinoma; Ewing sarcoma; Fallopian tube cancer; | Filters : [0] VEGF ligand inhibitor | Filters : [0] | Filters : [0] |
| bevacizumab biosimilar, Mylan/Biocon | Biocon Ltd; Mylan NV | Brain tumor; Cancer; Glioblastoma; Metastatic colorectal cancer; Metastatic renal cell carcinoma; Non- | VEGF ligand inhibitor | Launched (Brain tumor - India - Nov-2017; Metastatic colorectal cancer - India - Nov-2017; Non-small-cell lung | |

Click a drug name to read expert insights.

For more information contact Customer Service at [LS Product Support](#)